[1] Wen-Lin Kuo, et al. A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047. BMC Med. 2009 Dec 14;7:77. DOI:
10.1186/1741-7015-7-77[2] Murray Stewart T, et al. A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma. Cancer Chemother Pharmacol. 2021 Jan;87(1):135-144. DOI:
10.1007/s00280-020-04201-1 
